Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
Drug Discovery Today. Technologies|July 2, 2014
Proteomics: how to control highly dynamic patterns of millions of molecules and interpret changes correctly?André SchrattenholzALTEX|March 16, 2007
Neuronal cell culture from human embryonic stem cells as in vitro model for neuroprotectionAndré Schrattenholz, Martina KlemmCurrent Topics in Medicinal Chemistry|May 25, 2006
NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signallingAndré Schrattenholz, Vukic SoskicElectrophoresis|May 23, 2007
What does it need to be a biomarker? Relationships between resolution, differential quantification and statistical validation of protein surrogate biomarkersAndré Schrattenholz, Karlfried GroebeCurrent Medicinal Chemistry|June 10, 2008
What does systems biology mean for drug development?André Schrattenholz, Vukić SoskićALTEX|April 2, 2004
Neurotoxicity of active compounds--establishment of hESC-lines and proteomics technologies for human embryo- and neurotoxicity screening and biomarker identificationMartina Klemm, André SchrattenholzAnnals of the New York Academy of Sciences|June 12, 2010
Synchronization of posttranslational modifications during aging: Time is a crucial biological dimensionAndré Schrattenholz, Vukić Soskić, Karlfried GroebeJournal of Cellular Biochemistry|April 20, 2005
Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysisFrank Gillardon, André Schrattenholz, Bernd SommerExperimental Gerontology|January 25, 2008
Nonenzymatic posttranslational protein modifications in ageingVukić Soskić, Karlfried Groebe, André SchrattenholzMethods in Molecular Biology (Clifton, N.J.)|September 9, 2010
Systems biology approaches and tools for analysis of interactomes and multi-target drugsAndré Schrattenholz, Karlfried Groebe, Vukic SoskicPageof 5